An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future.

Qin, Albert; Urbanski, Raymond W; Yu, Lennex; Ahmed, Tasfia; Mascarenhas, John

Qin, Albert; Urbanski, Raymond W; Yu, Lennex; Ahmed, Tasfia; Mascarenhas, John.

Afiliação

Qin A; PharmaEssentia Corporation, Taipei, Taiwan.
Urbanski RW; PharmaEssentia USA Corporation, Burlington, MA, United States.
Yu L; PharmaEssentia Corporation, Taipei, Taiwan.
Ahmed T; PharmaEssentia USA Corporation, Burlington, MA, United States.
Mascarenhas J; Tisch Cancer Institute, Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, United States.

Front Oncol ; 13: 1109866, 2023.

Article em En | MEDLINE | ID: mdl-36776307

Palavras-chave

alternative dosing strategy; clinical study; interferon; myeloproliferative neoplasm; pegylated interferon; polycythemia vera; ropeginterferon alfa-2b

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2023 Tipo de documento: Article